Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy
Qinghua Wang, Meiling Li, Meng Yang, Yichen Yang, Fengju Song, Wei Zhang, Xiangchun Li, Kexin Chen
Abstract
mutation. These observations were validated in 9 independent LUAD cohorts. Our findings suggest that immune checkpoint blockade therapy may be efficacious for high-risk subtype of LUAD patients.
Topics & Concepts
Immune checkpointSubtypingOncologyBlockadeAdenocarcinomaImmunotherapyImmune systemInternal medicineCohortMedicineBiologyCancer researchCancerImmunologyReceptorComputer scienceProgramming languageCancer Immunotherapy and BiomarkersFerroptosis and cancer prognosisLung Cancer Treatments and Mutations